𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Valproate embryopathy: Clinical and cognitive profile in 5 siblings

✍ Scribed by Elizabeth K. Schorry; Sonya G. Oppenheimer; Howard M. Saal


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
142 KB
Volume
133A
Category
Article
ISSN
1552-4825

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Valproate embryopathy is a well recognized syndrome caused by prenatal exposure to the anticonvulsant valproic acid (Depakote). We report five half‐siblings with the same mother (four different fathers) who all have valproate embryopathy. Valproic acid was the sole anticonvulsant in all five pregnancies, with doses ranging from 500 to 2,000 mg per day. All children were examined by a clinical geneticist and developmental pediatrician, and had formal developmental testing. Mean birth weight at term was 2,900 g (range: 2,400–3,400 g). Common features in the five children included: flat, broad nasal bridge (5/5), hypoplastic midface (4/5), apparent hypertelorism/telecanthus (4/5), smooth philtrum (4/5), thin upper lip (5/5), long thin tapering fingers (4/5), hypoplastic 5th toenails (2/5), and irregularly placed toes (2/5). Less frequent features were micro/brachycephaly (2/5), cleft palate (1/5), duplication cyst of small intestine (1/5), and hemangioma (1/5). None had neural tube defect. Neuropsychologic testing of the three children older than 4 years of age showed cognitive ability in the low normal or borderline range (mean IQ = 83; range: 75–86), with significantly lower scores in adaptive behavior and motor skills. Study of this family offers insight into the potentially high risk of valproate embryopathy in exposed pregnancies, and affords a unique opportunity to study the variability of expression and cognitive profile of the syndrome within one family. © 2005 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Cognitive testing in early phase clinica
✍ Alex Collie; Paul Maruff; Peter J. Snyder; Miss Amanda Darekar; John P. Huggins 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

## Abstract ## Background It has been proposed that objective cognitive testing provides additional information to that collected via adverse event (AE) recordings. However, in clinical trials of compounds with potentially negative effects on cognition, the results of cognitive testing may overlap